← Back to Search

CAR T-cell Therapy

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 & 2
Waitlist Available
Research Sponsored by Tceleron Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment using a patient's own modified immune cells to target advanced prostate cancer that resists standard treatments. The modified cells are designed to find and destroy cancer cells by recognizing a unique marker on them. A similar treatment has shown improved survival in patients with advanced prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase 1: To evaluate the safety of TmPSMA-02 in adult patients with mCRPC
Phase 1: To identify the recommended Phase 2 dose of TmPSMA-02 administered in combination with LD chemotherapy
Phase 2: To evaluate the objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Secondary study objectives
Phase 1: To assess the clinical and manufacturing feasibility of TmPSMA-02
Phase 1: To evaluate the preliminary antitumor activity of TmPSMA-02 according to RECIST v1.1 and the PCWG3 criteria
Phase 2: Describe pharmacokinetic factors of TmPSMA-02 in peripheral blood
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TmPSMA-02Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Tceleron Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
34 Total Patients Enrolled
Tmunity TherapeuticsLead Sponsor
6 Previous Clinical Trials
137 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top